Why Progesterone Calms One Woman but Sends Another Into Panic: The Hidden Biology of Hormonal Sensitivity

Imagine going to bed feeling completely normal, only to wake up at three in the morning with your heart pounding, your thoughts racing, and an overwhelming sensation that something terrible is about to happen. You haven’t had a nightmare. Nothing frightening has occurred. You aren’t consciously worrying about anything. Yet your body is behaving as though you’re facing an immediate threat. You lie awake for hours, and by morning you’re exhausted, frightened, and struggling to understand what’s happening.

Now imagine that this begins happening repeatedly, sometimes around ovulation, sometimes during the days before menstruation, and sometimes without any predictable pattern as you approach your forties. You may begin experiencing irritability, brain fog, dizziness, gastrointestinal discomfort, heart palpitations, and a level of anxiety you’ve never experienced before. Your ability to tolerate ordinary stress deteriorates. Small problems feel overwhelming. Sleep becomes increasingly difficult, and eventually you start worrying about whether you’ll ever feel like yourself again.

You undergo hormone testing, and the results may come back within the laboratory’s reference ranges. You might be told that your symptoms are simply anxiety, ordinary aging, or an expected part of the menopausal transition. Perhaps you try progesterone because you’ve heard that it supports relaxation and sleep. For some women, it helps. For others, the experience is completely different: their anxiety intensifies, their mood deteriorates, or they begin feeling unusually agitated.

These symptom patterns are not specific to one condition, and they certainly don’t prove that progesterone is responsible. But they illustrate an important limitation in how we sometimes think about hormonal health. We tend to focus on the amount of hormone circulating in the bloodstream while paying less attention to the biological system receiving that hormonal signal.

After publishing my recent article about progesterone, allopregnanolone, and mast cell activation, I received messages from women describing severe hormonal sensitivity, sometimes dating back to puberty and becoming substantially worse during perimenopause. Some reported panic, insomnia, emotional instability, and symptoms that appeared to fluctuate with their natural menstrual cycles. Others described complicated histories involving chronic stress, trauma, gastrointestinal problems, inflammatory conditions, and sensitivity to medications or environmental exposures.

One woman described experiencing these patterns since she was approximately twelve years old. She had endured multiple layers of trauma, was approaching perimenopause, and described feeling as though her brain was on fire. What particularly interested me was that she wasn’t taking progesterone. Her symptoms appeared to follow her body’s own hormonal fluctuations.

Her message stayed with me because it raised a question that connects directly with the systems-biology work I’ve been developing at BiomeLogic.

What if some women aren’t experiencing a problem with how much progesterone they produce, but with how their nervous systems respond to changing progesterone and neurosteroid exposure?

What if two women have similar hormone concentrations, yet one experiences relaxation while the other develops severe anxiety, irritability, or panic? Could the difference involve the enzymes that metabolize progesterone, the receptors that respond to its metabolites, the nervous system’s adaptation to previous hormonal exposure, or the influence of stress and inflammation on neuronal signaling?

These are the questions I’ve been investigating through published reproductive neuroscience, neuroendocrinology, cellular metabolism, immunology, and systems biology. And some of the most compelling answers are beginning to emerge from controlled human research.

The science is challenging an important assumption about hormonal sensitivity

One of the most revealing findings in reproductive psychiatry is that women with severe premenstrual symptoms do not necessarily have abnormal circulating concentrations of estrogen or progesterone.

Researchers have demonstrated that, in certain women, the problem involves the nervous system’s response to normal ovarian hormone exposure rather than a straightforward excess or deficiency.

In October 2025, a study published in the American Journal of Psychiatry examined women with premenstrual dysphoric disorder, or PMDD, alongside healthy comparison participants. Researchers temporarily suppressed ovarian hormone production using leuprolide, then evaluated what happened when estradiol or progesterone was reintroduced.

The study included 34 women with PMDD and 76 healthy comparison participants. During ovarian suppression, the characteristic cyclical symptoms improved in the affected women. When ovarian steroids were reintroduced, anxiety, sadness, irritability, and mood swings increased in the susceptible group but not in the unaffected comparison group.

The researchers also found that irritability and mood swings were more closely associated with progesterone exposure than estradiol in this particular experimental setting.

This was an important replication of earlier findings because it demonstrated something that should fundamentally influence how we investigate severe hormonal sensitivity: ordinary ovarian hormone exposure can produce profoundly different neurological responses in different women.

It does not mean progesterone is inherently harmful, nor does it mean everyone who experiences premenstrual anxiety has PMDD. But it provides direct human evidence that the biological response to hormonal change can matter more than the absolute concentration of a hormone.

That distinction also helps explain why a woman can have relatively unremarkable hormone results while experiencing substantial symptoms.

A blood measurement tells us how much of a hormone is present at a particular moment. It does not directly measure receptor sensitivity, local neurosteroid concentrations within the brain, or how neuronal circuits respond to changing hormonal exposure.

And the nervous system is not exposed to progesterone alone. Progesterone is metabolized into several biologically active compounds, some of which directly influence neuronal communication.

One of the most important is allopregnanolone.

Progesterone can be converted into 5α-dihydroprogesterone through the action of 5α-reductase enzymes, including enzymes associated with SRD5A1. A subsequent reaction involving 3α-hydroxysteroid dehydrogenase activity, including certain AKR1C enzymes, produces allopregnanolone.

Allopregnanolone belongs to a group of substances called neurosteroids. Unlike reproductive hormones considered primarily in relation to the uterus, ovaries, or breast tissue, neurosteroids can directly influence the activity of receptors involved in brain signaling.

Allopregnanolone acts as a positive allosteric modulator of GABA-A receptors. GABA, or gamma-aminobutyric acid, is the principal inhibitory neurotransmitter in much of the mature central nervous system.

I often explain the GABA system as part of the brain’s braking mechanism. Glutamate generally promotes neuronal excitation, while GABA helps regulate excessive activity. This balance contributes to sleep, emotional regulation, sensory processing, and the normal functioning of circuits involved in fear and stress.

When allopregnanolone interacts with GABA-A receptors, it generally strengthens the inhibitory effects of GABA. This is one reason progesterone and its metabolites can produce calming, sedative, or sleep-promoting effects.

But the important detail is that allopregnanolone does not act on a fixed receptor system.

The receptors receiving its signal are continually adapting to their biochemical environment.

GABA-A receptors are assembled from different protein subunits that determine their functional properties. Some receptors are located primarily at synapses, where they participate in rapid inhibitory communication. Others contribute to longer-lasting background inhibition, sometimes called tonic inhibition.

Receptor subunits associated with genes such as GABRA4, GABRD, GABRG2, and GABRA5 have attracted attention because their expression, assembly, and functional properties may influence neurosteroid responsiveness.

In experimental models, changing neurosteroid exposure can alter receptor-subunit composition and neuronal responses. The effect may differ depending on whether exposure is increasing, remaining elevated, or declining.

This is known as receptor plasticity. It means that a receptor’s response can depend partly on the hormonal environment to which the nervous system has previously adapted.

Consider what happens during the menstrual cycle. Following ovulation, progesterone typically increases, changing the availability of downstream neurosteroids such as allopregnanolone. If pregnancy does not occur, progesterone declines toward menstruation. During pregnancy, progesterone and related neurosteroid exposure change substantially, followed by a rapid decrease after delivery. During perimenopause, hormonal patterns can become more variable as ovulation becomes less predictable.

The nervous system must continually adapt to these changing signals. In most women, this occurs without severe disruption. But some women appear particularly sensitive to certain hormonal transitions.

One hypothesis is that, in susceptible individuals, the timing or magnitude of receptor adaptation does not adequately match the changing neurosteroid environment.

There is emerging human research relevant to this possibility.

In a study published in Translational Psychiatry in December 2025, investigators examined menstrual-cycle changes in the expression of three GABA-A receptor-subunit genes: GABRD, GABRG2, and GABRA5. The study included 112 participants and assessed how peripheral gene-expression patterns related to cyclical changes in anxiety, irritability, and other psychiatric symptoms.

The investigators found that changes in the expression of these genes were associated with different patterns of menstrual-cycle-related emotional symptoms. Importantly, the results did not suggest that simply having more or less of one receptor-subunit transcript explained everything. Instead, the stability and direction of expression changes appeared relevant.

I find this especially interesting because it supports looking at the dynamics of receptor regulation rather than assuming a static receptor deficiency.

But this study measured gene expression in peripheral blood cells, not GABA-A receptor protein abundance or signaling within the human brain. These findings require replication and are not currently suitable for diagnosing progesterone sensitivity in individual women.

Still, the broader biological principle is important. The nervous system is responding not simply to a concentration, but to a changing signal within a regulatory network that has its own history of adaptation.

There is another layer that I think deserves attention: allopregnanolone is not the only neuroactive steroid produced or encountered by the nervous system.

Progesterone metabolism can produce other compounds, including pregnanolone and isoallopregnanolone. The nervous system is also exposed to neuroactive steroids such as pregnenolone sulfate and DHEA sulfate. These substances differ in their interactions with neuronal receptors.

Allopregnanolone and pregnanolone generally enhance GABA-A receptor-mediated inhibition, whereas pregnenolone sulfate and DHEA sulfate can reduce aspects of GABA-A signaling and influence excitatory receptor activity under experimental conditions. Isoallopregnanolone can oppose some of allopregnanolone’s effects.

Sulfation introduces another level of regulation. Steroid sulfotransferases attach sulfate groups to certain steroids, while steroid sulfatases remove them. These reactions alter the chemical properties, distribution, metabolism, and sometimes the receptor interactions of steroid molecules.

My interest is in how these different pathways interact to determine the neurosteroid environment to which the nervous system is exposed.

A woman may have sufficient progesterone but experience a different pattern of downstream metabolism or sensitivity to neurosteroid changes. However, measuring circulating neurosteroids does not currently provide a validated diagnostic explanation for PMDD or progesterone-related anxiety.

The important insight is not that every woman has a hidden metabolic defect. It is that the pathway from progesterone production to neurological response involves several regulatory steps, each with the potential to influence the final effect.

What childhood trauma, stress, and epigenetics may contribute

Another observation that has drawn my attention is the overlap between severe reproductive mood symptoms and histories of prolonged stress or childhood adversity.

I want to approach this carefully because having experienced trauma does not mean that trauma caused a woman’s hormonal symptoms. Similarly, many women with PMDD have no known trauma history.

However, there is human evidence demonstrating an association.

A 2022 study published in BMC Medicine examined 11,973 women and investigated the relationship between adverse childhood experiences and probable premenstrual disorders. Women who reported four or more adverse childhood experiences had approximately 2.46 times the adjusted prevalence of these disorders compared with women reporting none.

The study also found a stronger association with probable PMDD than with less severe premenstrual symptoms.

Because this was a cross-sectional investigation, it cannot establish that trauma causes PMDD or identify the biological mechanisms involved. But it raises an important question about the long-term interaction between stress regulation and reproductive hormone sensitivity.

When the body encounters a threatening or stressful situation, the hypothalamic–pituitary–adrenal axis becomes involved. The hypothalamus releases corticotropin-releasing hormone, which stimulates pituitary ACTH secretion and subsequent cortisol production by the adrenal glands.

Cortisol participates in regulating metabolism, immune signaling, and the body’s response to stress. Normally, negative-feedback mechanisms help control this response.

But chronic or repeated stress can influence the regulation of these pathways.

Two genes I have been particularly interested in are FKBP5 and NR3C1. NR3C1 encodes the glucocorticoid receptor, which helps cells respond to cortisol. FKBP5 encodes a protein involved in regulating glucocorticoid receptor function and feedback sensitivity.

These pathways participate in how the body detects, responds to, and eventually regulates stress signals.

Epigenetic regulation adds another dimension. DNA methylation, histone modifications, and chromatin remodeling influence how genes are expressed without changing the underlying DNA sequence.

Under certain conditions, stress-related signaling can influence these processes. This provides a possible mechanism through which previous experiences can interact with long-term physiological regulation.

But the relationship is not deterministic. Epigenetic modifications are tissue-specific, may change over time, and cannot be inferred simply from a person’s trauma history.

What interests me is whether differences in stress-system regulation can influence how the brain responds to later fluctuations in reproductive hormones.

This possibility becomes particularly relevant during perimenopause.

In a human study involving 52 women during the menopausal transition or early postmenopause, researchers evaluated estradiol variability, stressful life events, and subsequent depressive symptoms over fourteen months.

Greater estradiol variability predicted greater depressive symptoms primarily among women who had experienced a higher number of recent highly stressful life events. Estradiol variability was also associated with greater sensitivity to social rejection during laboratory stress testing.

This does not prove that psychological stress changes GABA-A receptor composition or causes allopregnanolone intolerance. But it provides evidence that reproductive hormone variability and psychosocial stress can interact in ways relevant to mood regulation.

Another human investigation examined 50 perimenopausal women with depressive symptoms and found that greater estradiol variability and the absence of progesterone concentrations consistent with ovulation were associated with greater depressive symptom burden.

These findings are interesting because they suggest that the pattern of hormone exposure may matter, particularly during periods when ovarian function becomes increasingly unpredictable.

I also find the relationship between reproductive hormones and epigenetic regulation especially compelling.

In a 2017 study, researchers compared cultured lymphoblastoid cells from women with PMDD and unaffected controls. The investigators identified differences involving the ESC/E(Z) epigenetic regulatory complex, including genes such as MTF2, PHF19, and SIRT1.

The cells also showed different responses to exposure to ovarian steroids.

This is important because it demonstrates that cells from women with documented ovarian hormone sensitivity can exhibit differences in gene-regulatory responses under experimental conditions.

However, these were cultured peripheral cells. The findings do not establish that the same patterns exist in particular brain regions, nor do they prove that modifying these genes would resolve clinical symptoms.

My broader investigation is whether differences in stress regulation, neurosteroid signaling, and epigenetic responses could help explain why certain women become particularly sensitive to reproductive transitions.

I don’t view this as a simple story in which trauma permanently damages the nervous system. The brain remains capable of adaptation, and reproductive mood symptoms involve multiple potential contributing mechanisms.

Rather, I am interested in understanding whether previous biological exposures can influence how particular neural circuits respond when their hormonal environment changes.

Neuroinflammation, mitochondrial metabolism, and the cellular environment

When discussing progesterone sensitivity, most attention goes to hormone receptors. But receptors operate within neurons, and those neurons depend on a complex physiological environment.

The brain contains immune cells called microglia, which participate in immune surveillance, tissue maintenance, and responses to injury. Astrocytes help regulate extracellular ions, neurotransmitter handling, metabolic support, and interactions between neurons and blood vessels.

Inflammatory mediators such as IL-1β, IL-6, and TNF-α can influence neuronal signaling under certain conditions.

One pathway I have been examining involves the neuronal potassium–chloride cotransporter KCC2, encoded by SLC12A5.

KCC2 helps maintain intracellular chloride concentrations in many mature neurons. This is important because the electrical effects of GABA-A receptor activation depend partly on the chloride gradient across the neuronal membrane.

In certain experimental systems, microglial signaling involving BDNF and its receptor TrkB can alter KCC2 function and change how neurons respond to GABA.

This demonstrates that inhibitory neurotransmission depends not only on the receptor receiving the signal, but also on the electrical state of the cell.

However, this particular pathway is most clearly demonstrated in specific experimental models, including pain-processing circuits. It has not been established as a general explanation for progesterone-associated panic, PMDD, or perimenopausal anxiety.

The reason I find it interesting is that it illustrates a larger biological principle: a hormone metabolite may interact with an apparently functional receptor, while the final electrical response depends on the broader cellular environment.

This connects with another area of my work involving mitochondrial function and cellular redox metabolism.

Mitochondria are not simply structures responsible for generating ATP. They also participate in calcium regulation, cellular signaling, oxidative stress responses, and steroid hormone synthesis.

In steroid-producing cells, the mitochondrial enzyme CYP11A1 converts cholesterol into pregnenolone, which can subsequently participate in progesterone synthesis.

These biochemical reactions involve coordinated enzyme systems and reducing equivalents, including NADPH-dependent processes.

NADPH is important because it provides reducing power for numerous biosynthetic reactions and helps support cellular antioxidant defense.

One major example involves glutathione. Reduced glutathione contributes to antioxidant regulation, and NADPH supports its regeneration through glutathione reductase.

Cells continuously generate reactive oxygen species, including hydrogen peroxide, during normal metabolism. At controlled concentrations, these molecules participate in cellular signaling. When their production substantially exceeds the capacity of protective systems, oxidative stress can interfere with normal protein function and metabolism.

My interest is whether significant disturbances in cellular redox conditions could influence steroid-metabolizing enzymes or the metabolic environment supporting neuronal signaling.

This remains a hypothesis in the context of hormonal sensitivity. We cannot conclude that PMDD or progesterone intolerance generally results from inadequate NADPH, impaired glutathione recycling, or mitochondrial dysfunction.

Nevertheless, neurons require substantial energy to maintain normal electrical activity. The sodium–potassium ATPase continually consumes ATP to preserve the ion gradients necessary for neuronal communication.

Transport systems such as KCC2 depend indirectly on those ion gradients.

Under significant metabolic stress, disturbances in energy production can affect the cellular conditions required for normal neuronal activity.

This is why I am interested in mitochondrial physiology when reviewing complex cases involving fatigue, autonomic symptoms, inflammatory conditions, and neurological complaints.

But it is also important to distinguish the physiological requirement for mitochondrial energy from a clinically demonstrated mitochondrial disorder.

A woman experiencing anxiety or insomnia should not automatically be assumed to have mitochondrial dysfunction simply because neuronal signaling requires ATP.

The question is whether there is meaningful evidence of metabolic pathology in her particular case and whether that pathology could plausibly explain her symptoms.

The gut microbiome, bile acids, and the wider hormonal environment

Another major focus of my work at BiomeLogic is intestinal microbial metabolism, particularly the relationship between colonocyte energy production, bile-acid transformations, epithelial barrier physiology, and systemic immune signaling.

One molecule that has been central to my research is butyrate.

Butyrate is produced when certain intestinal microorganisms ferment dietary fibers and related substrates. It serves as an important energy source for colonocytes and participates in maintaining intestinal epithelial physiology.

Butyrate also has signaling properties.

At sufficient intracellular concentrations, it can inhibit certain histone deacetylase enzymes, commonly called HDACs.

HDACs participate in regulating histone acetylation and gene accessibility, providing a biochemical connection between cellular metabolism and gene regulation.

This interests me because it demonstrates how microbial metabolites can influence host cellular pathways.

However, the concentration of butyrate produced in the colon is not equivalent to the concentration reaching the brain. Much of the butyrate generated by intestinal microorganisms is consumed by colonocytes or metabolized by other tissues.

Therefore, we cannot conclude that changes in intestinal butyrate production directly alter human GABA-A receptor expression, reverse trauma-related epigenetic changes, or treat PMDD.

What I am investigating is whether significant disturbances in intestinal metabolism may influence systemic physiology through immune signaling, metabolic regulation, and interactions involving the gut–brain axis.

Steroid metabolism provides another interesting connection.

Certain intestinal microorganisms express enzymes such as beta-glucuronidases and sulfatases, which can modify conjugated compounds. These reactions can influence the handling of some steroid metabolites and other endogenous molecules within the intestine.

The liver also plays a central role in steroid metabolism, conjugation, and biliary excretion.

This is particularly relevant to my ongoing investigation of bile-acid physiology.

Primary bile acids are synthesized from cholesterol in the liver. After reaching the intestine, they undergo microbial transformations, including deconjugation and, in the case of certain organisms, conversion into secondary bile acids.

Bile acids are not merely detergents required for dietary fat absorption. They also participate in signaling through receptors including FXR and TGR5, influencing metabolic and immune regulation.

Changes in bile-acid composition can therefore affect several aspects of gastrointestinal and systemic physiology.

My interest is whether disturbances in intestinal microbial metabolism, bile-acid signaling, and inflammatory regulation could contribute to the broader physiological environment in which reproductive hormonal symptoms occur.

That does not mean that an abnormal microbiome or secondary bile-acid profile is an established cause of hormonal anxiety.

And a stool test cannot determine whether allopregnanolone is acting normally within the brain.

Microbial abundance also does not directly establish metabolic activity. The presence of butyrate-producing organisms, for example, does not prove how much butyrate is being produced, consumed, or absorbed.

These limitations are important because the goal is not to identify every possible biochemical connection and assume that it contributes to a person’s symptoms.

The goal is to determine whether a particular pathway has enough clinical and mechanistic support to warrant further investigation.

For women who experience significant gastrointestinal dysfunction alongside hormonal symptoms, reviewing the intestinal findings may be relevant. For women without gastrointestinal complaints or other supporting evidence, extensive microbiome investigations may offer little value.

I believe a systems-biology approach should help distinguish between those situations rather than recommend the same testing for everyone.

Where mast cells, histamine, and autonomic symptoms may overlap

Another pattern that interests me is the overlap between hormonal fluctuations and symptoms that may involve immune or autonomic signaling.

Some women describe flushing, itching, gastrointestinal discomfort, palpitations, dizziness, or episodes of unusual physical reactivity that seem to become more noticeable during particular phases of the menstrual cycle.

Mast cells are immune cells capable of releasing histamine, prostaglandins, leukotrienes, tryptase, and other signaling mediators.

These compounds can influence vascular function, gastrointestinal physiology, peripheral sensory signaling, and inflammatory responses.

Estrogen and progesterone can influence immune-cell activity, although their effects depend on the particular receptor, cell type, concentration, and physiological context.

It would be an oversimplification to claim that estrogen always activates mast cells or progesterone always suppresses them.

My interest is in how peripheral mediator release and autonomic responses may interact with central nervous-system regulation in women who have established immune or autonomic conditions.

For example, recurrent palpitations, gastrointestinal discomfort, and disrupted sleep can increase the physical burden of an illness. Those symptoms may coexist with reproductive hormone sensitivity, and each process may influence the overall experience.

But mast cell activation syndrome, commonly called MCAS, requires appropriate clinical and biochemical evidence. Anxiety, food intolerance, or flushing alone is not sufficient to establish the diagnosis.

When clinically indicated, one important biomarker involves comparing serum tryptase measured during a suspected systemic mast-cell activation episode with the individual’s baseline level.

A commonly used criterion is an event-related increase exceeding 20% of baseline plus 2 ng/mL. Other mediator measurements, including urinary N-methylhistamine, leukotriene E4, and prostaglandin D2 metabolites, may be considered in selected cases, although their interpretation has limitations.

These tests investigate mast-cell mediator release. They do not diagnose hormonal sensitivity, and they should not be used simply because a woman experiences premenstrual anxiety.

This distinction is especially important when someone has symptoms spanning several systems.

The correct response is not to assume that one condition explains everything, but to determine which problems have established evidence and which remain possible contributing mechanisms.

What I would actually investigate in a complex hormonal case

One of the most important lessons from the research is that identifying an interesting mechanism is not the same as identifying the cause of an individual’s symptoms.

When I review a complex case, my first priority is reconstructing the chronology rather than starting with an extensive collection of biomarkers.

I want to understand when the symptoms began, how they have changed over time, which physiological systems appear to be involved, and whether the pattern is consistent with a recognized clinical condition.

For example, a woman who experiences severe anxiety and irritability during the luteal phase, followed by substantial relief after menstruation begins, may have a different pattern from a woman whose anxiety is present throughout the month but becomes worse before menstruation.

The first pattern may raise suspicion for PMDD. The second may represent premenstrual exacerbation of an existing disorder.

These conditions require different clinical considerations.

The most useful starting point is often prospective daily symptom tracking across at least two menstrual cycles.

A validated instrument such as the Daily Record of Severity of Problems, or DRSP, can help establish whether symptoms follow a reproducible menstrual pattern.

I regard this as particularly important because it measures the actual clinical phenomenon rather than relying on a hormone concentration as a substitute for symptoms.

If the timing is unclear, carefully documenting menstrual dates, probable ovulation, sleep disturbances, mood changes, and functional impairment may reveal patterns that are difficult to recognize retrospectively.

In selected cases, laboratory measurements may help answer specific endocrine questions. For example, correctly timed luteal progesterone testing can help assess whether ovulation has occurred, although the appropriate timing depends on the woman’s cycle rather than automatically testing on day 21.

Estradiol and FSH measurements may be useful for particular clinical indications, but isolated measurements often have limited value during the variable hormonal environment of perimenopause.

Other investigations may be appropriate when symptoms or clinical history suggest an additional explanation.

Thyroid function can be relevant when palpitations, anxiety, temperature intolerance, or menstrual abnormalities raise concern for thyroid disease. A complete blood count and ferritin may be informative when fatigue, heavy menstrual bleeding, or iron deficiency are suspected. Cardiovascular evaluation may be necessary when palpitations, fainting, chest symptoms, or unexplained tachycardia are present.

Sleep disturbances also deserve direct evaluation rather than being attributed automatically to hormones.

And when there is a history of medication sensitivity, the exact drug, formulation, dose, timing, and relationship to symptom changes become important.

What about the more advanced biomarkers that interest me?

Research involving allopregnanolone, GABA-A receptor-subunit expression, epigenetic regulators, cortisol feedback, and neuroinflammatory signaling may eventually help identify biologically distinct groups of women.

But many of these markers are currently investigational.

A blood measurement of GABRD or GABRG2 expression cannot establish how a woman’s brain is responding to progesterone. FKBP5 methylation cannot reliably diagnose trauma-related hormonal sensitivity. A plasma allopregnanolone concentration cannot reveal every aspect of receptor function. And stool microbiome profiles cannot establish the cause of PMDD.

The question I would ask is whether the proposed biomarker has been validated against a meaningful clinical outcome.

Does it distinguish affected women from unaffected women with sufficient accuracy? Does it provide information beyond a careful clinical history? Would knowing the result change a medical decision? And is there evidence that modifying the pathway improves outcomes?

These are essential questions because the purpose of testing should be to reduce uncertainty, not simply produce more data.

In my independent research, I am interested in developing a more precise framework for reviewing complex cases where reproductive symptoms overlap with gastrointestinal, immune, autonomic, or metabolic abnormalities.

That involves examining candidate mechanisms, competing explanations, and the evidence required to distinguish them.

I do not believe every woman experiencing perimenopausal anxiety needs a comprehensive microbiome analysis, mitochondrial assessment, genetic interpretation, or specialized inflammatory testing.

But when someone has a substantial multisystem history, existing investigations may contain clues that deserve to be interpreted together rather than in isolation.

That is where detailed mechanistic case reconstruction can become valuable.

Why this changes how I think about women’s hormonal health

The more I examine this subject, the less convincing I find explanations that reduce every symptom to estrogen dominance, progesterone deficiency, or a generalized imbalance between reproductive hormones.

Those labels may describe selected hormonal patterns, but they do not adequately explain the diversity of neurological responses women can experience.

Two women may enter perimenopause at similar ages, yet one experiences only modest menstrual changes while the other develops severe insomnia, anxiety, and functional impairment.

One woman may respond favorably to micronized progesterone, while another experiences significant mood symptoms after starting the same general class of treatment.

A woman with PMDD may respond differently to ordinary ovarian steroid exposure despite having hormone concentrations comparable to those of an unaffected woman.

These observations don’t prove that every woman has a different molecular disorder. They demonstrate why the clinical response cannot be predicted from a hormone concentration alone.

The strongest human evidence currently supports altered sensitivity to reproductive hormone exposure in PMDD and the importance of hormone variability in some perimenopausal mood symptoms.

Research also supports the involvement of neurosteroid signaling and suggests that receptor regulation, cellular responses to ovarian steroids, and interactions with stress-related pathways deserve further attention.

The evidence is less developed for the direct involvement of mitochondrial redox metabolism, microbiome-derived metabolites, bile-acid composition, or specific neuroimmune pathways in these symptoms.

Those remain areas for careful investigation, not established explanations.

And that distinction matters to me.

Because the purpose of mechanistic analysis is not to make every case sound more complicated. It is to identify which biological explanations are sufficiently supported, which remain plausible but uncertain, and what information would distinguish one hypothesis from another.

For women experiencing debilitating symptoms, the most useful outcome is not an impressive list of pathways.

It is a clearer understanding of what is already known, what may be contributing, and which questions deserve the attention of their medical team.

Evidence-based treatments, including certain SSRIs, psychological interventions, and selected hormonal strategies, remain important for clinically diagnosed premenstrual disorders. Complex mechanistic theories should not replace treatments supported by human clinical evidence.

But treatment and investigation are not mutually exclusive.

In particularly complex presentations, additional analytical work may help organize a fragmented history and identify overlooked interactions between established conditions.

Why I’m expanding this investigation through BiomeLogic

Through my work at BiomeLogic, I have spent considerable time examining the intersection of gastrointestinal physiology, immune signaling, autonomic dysfunction, cellular metabolism, and complex chronic conditions.

The messages I’ve received following my recent articles have encouraged me to give greater attention to women whose reproductive hormonal symptoms overlap with these other physiological systems.

I’m particularly interested in understanding complicated presentations involving severe cyclical anxiety or insomnia, difficult perimenopausal transitions, unusual reactions to progesterone or other hormonal treatments, and hormonal changes occurring alongside significant gastrointestinal, immune-related, or autonomic symptoms.

My work focuses on independent mechanistic case analysis. I review available medical histories, prior laboratory investigations, medications, symptom timelines, and existing clinical findings to reconstruct the possible biological relationships within a case.

The objective is to distinguish established mechanisms from hypotheses, identify competing explanations, and develop an organized framework that can be evaluated with the person’s licensed healthcare team.

This is not medical diagnosis or treatment, and I do not replace gynecologists, psychiatrists, endocrinologists, or other licensed clinicians. The work is most relevant when a person has a complex medical history spanning several systems and needs a more detailed synthesis of information that has already been collected.

If you are experiencing severe hormonal sensitivity alongside gastrointestinal dysfunction, autonomic symptoms, immune-related complaints, or other complex chronic health issues, I welcome inquiries about whether a systems-biology case review would be appropriate.

You can begin with the free BiomeLogic case-fit intake form. It takes approximately five minutes, requires no payment or medical files, and allows me to review a brief description of your situation before determining whether a more comprehensive analysis is appropriate.

If your case is a fit, you will receive information about the next steps, the scope of the analysis, and the consultation fee before making a commitment. Any detailed records can be submitted through the designated intake process rather than unsecured email.

I believe women experiencing complex symptoms deserve investigations that are both scientifically rigorous and appropriately individualized. Not every case requires advanced testing, and not every symptom has a hidden molecular explanation. But when several physiological systems are involved, the relationships between those systems may deserve closer examination.

I keep returning to the woman who described experiencing these symptoms since puberty. Her history does not establish which pathway is responsible, but it highlights how long someone can live with recurring symptoms without a satisfactory explanation.

For some women, reproductive hormonal changes are relatively uneventful. For others, those same transitions are associated with profound changes in sleep, emotional regulation, cognition, and physical well-being.

Understanding those differences requires looking beyond hormone concentrations alone.

Because progesterone doesn’t act in isolation. Neither do allopregnanolone, GABA, cortisol, immune mediators, or the metabolites produced by intestinal microorganisms.

They participate in a larger biological system whose function depends on receptor regulation, cellular metabolism, tissue physiology, and the body’s capacity to adapt.

Perhaps one of the most overlooked questions in women’s hormonal health is not simply how much hormone the body produces, but what determines how the nervous system responds when that hormone changes.

That is the question I am continuing to investigate through my independent research and work at BiomeLogic.

And for women living with severe, recurrent hormonal symptoms, I believe it is a question worth taking seriously.

Mohammed Attallah
Founder, BiomeLogic
Mechanistic Health & Systems Biology Consultant
www.biomelogic.net